News & Updates
Filter by Specialty:
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
25 Aug 2022
FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.
FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
23 Aug 2022
Live birth after breast cancer may improve overall survival
Women who become pregnant and have a live birth following a diagnosis of breast cancer may have better overall survival (OS) outcomes than those without live births post-cancer, according to a study presented at ESHRE 2022.